- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Maréchal-Jamil: Opportunities for Biosimilars in 2019
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes opportunities for biosimilars in the year ahead.
Transcript
This year for us is very special because we have European elections. It's a time when the political agenda gets quite reset for another 5 years, so it's very important and for us, it's important that the parliament that will be elected in May and then the European Commission that will be formed then in the fall all have a strategic agenda for health. That's very important for us, but more importantly that they have a reserved place for biosimilars to play an important role in that agenda.
Two points: I think, in Europe, there's a big focus on reducing inequalities in access, and biosimilars are very obvious and readily available to contribute to meeting that objective, so I think we're calling on the institution this year [in a very] big [way] to to have that strategic inclusion of biosimilars in meeting their health objectives.
The other bit is more on the industrial side of things, where biosimilars were born here in Europe because of how the system was set up early on, their legal framework and everything, but we haven't fared very well in manufacturing capability and know-how; that really needs to be nurtured because the the needs are growing in Europe and elsewhere, and I think it's important that we nurture that for the long-term.
So 2 agendas: one more on the equity, creating greater equity, and the other more on the industrial policy side. So this is our big agenda for 2019.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
